Chronic Neuropathic Pain Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Chronic Neuropathic Pain remains an active clinical development field. The field is increasingly separating symptomatic benefit from disease modification, while enrichment, digital measures and fluid or imaging biomarkers reshape trial design. The PatSnap evidence set used here contains 1,136 matched trial records and 263 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| CTR20262709 | Mirogabalin Besilate | Not Applicable; 进行中 （尚未招募） | Nanjing Zenkom Pharmaceutical Co., Ltd. | China | (24小时) | Timing not listed |
| ChiCTR2600128030 | Intervention not normalized | Not Applicable; Not yet recruiting | Beijing Tongren Hospital | China | Tear inflammatory factors and neurotransmitters (Before and after the operation, D1, W1, M1, M3, M6, M12); Neurological function and imaging (Before and after the operation, M1, M3, M6, M12) | 2027-12-31 |
| NCT07699770 | Crisugabalin | Phase 4; Not yet recruiting | Tangdu Hospital | China | Numeric Rating Scale (NRS) Pain Score (Change from baseline in the Numeric Rating Scale (NRS) pain score after 2 and…) | 2027-10-31 |
| CTR20262637 | Mirogabalin Besilate | Not Applicable; 进行中 （尚未招募） | Nanjing Healthnice Pharmaceutical Co., Ltd. | China | (给药前60min内至采血结束) | Timing not listed |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Efficacy and Safety of Pregabalin and Alpha‐Lipoic Acid Combination in Patients With Painful Diabetic Peripheral Neuropathy: A Randomized, Open‐Label, Non‐Inferiority, Phase <scp>IV</scp> Clinical Trial and Subgroup Analysis ( <scp>OPTIMUM Study</scp> ) (Phase 4): the indexed record reports VAS(12-week): Difference (LSM) = 3.46(95.0% CI, -4.94 to 11.87); VAS(12-week) = -19.73 mm ( 18.94); VAS(12-week) = -23.28 mm ( 18.15).
- 8-PUB: High-Dose Crisugabalin Significantly Improving the Pain Symptoms in Patients with Diabetic Peripheral Neuropathic Pain (DPNP) (Not Applicable): the indexed record reports ADPS(4-week) = -3.983 point ( 1.556).
- Influence of ginger root extract supplementation on the microbiota-gut-brain axis in individuals with sciatica: Study protocol for a double-blind, placebo-controlled randomized trial (Phase 2): the indexed record reports PSQ-20(reduced pain) = 2.0 point; PSQ-20(reduced pain) = -8.0 point.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Mirogabalin Besilate (Approved; CACNA2D1 x CACNA2D2), Crisugabalin (Approved; CACNA2D1). Company & Deal Intelligence records identify sponsor context for Nanjing Zenkom Pharmaceutical Co., Ltd. (836342), Beijing Tongren Hospital, Tangdu Hospital, Nanjing Healthnice Pharmaceutical Co., Ltd.. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Validated biomarkers that bridge biological activity to meaningful function.
- Longer follow-up that distinguishes transient symptom change from altered disease trajectory.
- Decentralized and digital measures that reduce noise without increasing patient burden.
- Trials designed around genetically or biologically defined subgroups.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Chronic Neuropathic Pain has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
